EGFR and oral cavity squamous cell carcinoma: Owing to the targeted therapy against EGFR in many cancers in the body, clinical trials are underway inhibiting the EGFR and/or its downstream signal transduction pathways in the initial and intermediate stages of cancer development, thereby presenting a promising strategy for the development of chemotherapeutic and chemopreventive agents in oral squamous cell carcinoma.